These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 17327941)

  • 1. Increased concentration of tissue-degrading matrix metalloproteinases and their inhibitor in complicated diverticular disease.
    Rosemar A; Ivarsson ML; Börjesson L; Holmdahl L
    Scand J Gastroenterol; 2007 Feb; 42(2):215-20. PubMed ID: 17327941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Balance between matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP) in the cervical mucus plug estimated by determination of free non-complexed TIMP.
    Becher N; Hein M; Uldbjerg N; Danielsen CC
    Reprod Biol Endocrinol; 2008 Sep; 6():45. PubMed ID: 18826601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of matrix metalloproteinases, their tissue inhibitors, and osteopontin in the wall of thoracic and abdominal aortas with dilatative pathology.
    Lesauskaite V; Epistolato MC; Castagnini M; Urbonavicius S; Tanganelli P
    Hum Pathol; 2006 Aug; 37(8):1076-84. PubMed ID: 16867871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase expression in ileal carcinoids, lymph nodes and liver metastasis with prognosis and survival.
    Voland P; Besig S; Rad R; Braun T; Baur DM; Perren A; Langer R; Höfler H; Prinz C
    Neuroendocrinology; 2009; 89(1):66-78. PubMed ID: 18708724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin.
    Massi D; Franchi A; Ketabchi S; Paglierani M; Pimpinelli N; Santucci M
    Hum Pathol; 2003 Jan; 34(1):80-8. PubMed ID: 12605370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix-Metallo-Proteinases and their tissue inhibitors in radiation-induced lung injury.
    Yang K; Palm J; König J; Seeland U; Rosenkranz S; Feiden W; Rübe C; Rübe CE
    Int J Radiat Biol; 2007 Oct; 83(10):665-76. PubMed ID: 17729161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between matrix metalloproteinases/tissue inhibitors of matrix metalloproteinases systems and autoantibody patterns in systemic sclerosis.
    Montagnana M; Volpe A; Lippi G; Caramaschi P; Salvagno GL; Biasi D; Bambara LM; Guidi GC
    Clin Biochem; 2007 Aug; 40(12):837-42. PubMed ID: 17493602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the human lens: implications for cortical cataract formation.
    Sachdev NH; Di Girolamo N; Nolan TM; McCluskey PJ; Wakefield D; Coroneo MT
    Invest Ophthalmol Vis Sci; 2004 Nov; 45(11):4075-82. PubMed ID: 15505058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue.
    Matsunaga Y; Koda M; Murawaki Y
    Res Commun Mol Pathol Pharmacol; 2004; 115-116():143-50. PubMed ID: 17564313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors.
    Fondard O; Detaint D; Iung B; Choqueux C; Adle-Biassette H; Jarraya M; Hvass U; Couetil JP; Henin D; Michel JB; Vahanian A; Jacob MP
    Eur Heart J; 2005 Jul; 26(13):1333-41. PubMed ID: 15827062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost.
    Oh DJ; Martin JL; Williams AJ; Peck RE; Pokorny C; Russell P; Birk DE; Rhee DJ
    Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):953-63. PubMed ID: 16505029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinase, collagens, and Ki67 antigen in pleural malignant mesothelioma: an immunohistochemical and electron microscopic study.
    Hirano H; Tsuji M; Kizaki T; Sashikata T; Yoshi Y; Okada Y; Mori H
    Med Electron Microsc; 2002 Mar; 35(1):16-23. PubMed ID: 12111403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and distribution of MMPs and TIMPs in human uveal melanoma.
    Lai K; Conway RM; Crouch R; Jager MJ; Madigan MC
    Exp Eye Res; 2008 Jun; 86(6):936-41. PubMed ID: 18423620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression.
    Polyakova V; Hein S; Kostin S; Ziegelhoeffer T; Schaper J
    J Am Coll Cardiol; 2004 Oct; 44(8):1609-18. PubMed ID: 15489093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of matrix metalloproteinases and their endogenous tissue inhibitors in skin lesions from patients with tuberous sclerosis.
    Papakonstantinou E; Dionyssopoulos A; Aletras AJ; Pesintzaki C; Minas A; Karakiulakis G
    J Am Acad Dermatol; 2004 Oct; 51(4):526-33. PubMed ID: 15389186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.
    Curran S; Dundas SR; Buxton J; Leeman MF; Ramsay R; Murray GI
    Clin Cancer Res; 2004 Dec; 10(24):8229-34. PubMed ID: 15623598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with different types of scars and keloids.
    Ulrich D; Ulrich F; Unglaub F; Piatkowski A; Pallua N
    J Plast Reconstr Aesthet Surg; 2010 Jun; 63(6):1015-21. PubMed ID: 19464975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of blood sampling procedure on plasma concentrations of matrix metalloproteinases and their tissue inhibitors.
    Rossignol P; Cambillau M; Bissery A; Mouradian D; Benetos A; Michel JB; Plouin PF; Chatellier G; Jacob MP
    Clin Exp Pharmacol Physiol; 2008 Apr; 35(4):464-9. PubMed ID: 18307742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.